Abbvie Inc (NYSE:ABBV) Shorts Decreased By 3.51%

AbbVie Inc. (NYSE:ABBV) Corporate Logo

During 2018 Q2 the big money sentiment increased to 0.94. That’s change of 0.24, from 2018Q1’s 0.7. 55 investors sold all, 614 reduced holdings as AbbVie Inc. ratio increased. 524 rose stakes while 107 funds bought stakes. Funds hold 1.00 billion shares thus 5.08% less from 2018Q1’s 1.06 billion shares.
Smith Moore & reported 0.68% in AbbVie Inc. (NYSE:ABBV). Jacobs And Ca stated it has 1.17% of its capital in AbbVie Inc. (NYSE:ABBV). Ogorek Anthony Joseph Ny Adv invested in 0.08% or 1,161 shs. Chatham Capital reported 75,934 shs or 1.85% of all its holdings. Oxbow Advsr Ltd Llc holds 66,236 shs. Bahl & Gaynor holds 2.48% or 2.56M shs. Homrich And Berg invested 0.13% in AbbVie Inc. (NYSE:ABBV). Lederer & Assocs Investment Counsel Ca owns 12,310 shs. Bridges Investment Management Inc accumulated 123,110 shs or 0.51% of the stock. Jennison Assocs Ltd holds 0.02% or 222,278 shs. Advisor Prtnrs Limited Com has invested 0.66% of its capital in AbbVie Inc. (NYSE:ABBV). Perigon Wealth Mgmt Lc has invested 0.46% of its capital in AbbVie Inc. (NYSE:ABBV). Boltwood Capital Mngmt has invested 0.56% in AbbVie Inc. (NYSE:ABBV). 129,872 were accumulated by Braun Stacey Associate. Adage Prns Grp Ltd Com has 1.02M shs for 0.22% of their capital.

AbbVie Inc. registered $9.85 million net activity with 2 insider buys and 3 sales since June 15, 2018. On Friday, June 15 RICHMOND TIMOTHY J. sold $1.75 million worth of AbbVie Inc. (NYSE:ABBV). $99,909 worth of AbbVie Inc. (NYSE:ABBV) shs were bought by RAPP EDWARD J. 42,450 shs were sold by Gosebruch Henry O, worth $3.82 million. The insider TILTON GLENN F bought $496,274.

Abbvie Inc (NYSE:ABBV) reported a decrease of 3.51% in shorted shares. FINRA announced in December ABBV’s total 31.44M shorted shares. That’s 3.51% down from 32.58 million shares. 8 days will cost ABBV with 4.02M average volume to restore its previous position. Abbvie Inc’s shorted shares float is 2.08%.

The stock decreased 3.73% or $3.37 during the last trading session, touching $86.96.AbbVie Inc. is uptrending after having risen 6.26% since December 8, 2017. ABBV has 6.74 million volume or 24.69% up from normal. ABBV underperformed the S&P500 by 9.36%.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide.The company has $130.81 billion market cap. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.The P/E ratio is 18.16. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

AbbVie Inc. (NYSE:ABBV) Ratings Coverage

In total 5 analysts cover AbbVie (NYSE:ABBV). “Buy” rating has 2, “Sell” are 2, while 1 are “Hold”. (NYSE:ABBV) has 40% bullish analysts. 8 are the (NYSE:ABBV)’s ratings reports on Dec 8, 2018 according to StockzIntelligence Inc. On Monday, June 11 Argus Research maintained AbbVie Inc. (NYSE:ABBV) with “Buy” rating. On Thursday, October 4 the rating was maintained by Bank of America with “Buy”. On Monday, November 5 the stock has “Underperform” rating by BMO Capital Markets. On Tuesday, November 6 the rating was maintained by Argus Research with “Buy”. On Wednesday, August 22 the firm earned “Buy” rating by Bank of America. On Friday, June 22 the stock of AbbVie Inc. (NYSE:ABBV) earned “Sell” rating by Credit Suisse. On Monday, July 30 the company was maintained by Bank of America.

For more AbbVie Inc. (NYSE:ABBV) news brought out recently go to: Streetinsider.com, Investorplace.com, Prnewswire.com, Seekingalpha.com or Investorplace.com. The titles are as follows: “AbbVie (ABBV) Says IMBRUVICA Combo Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR in Some CLL Patients – StreetInsider.com” brought out on December 04, 2018, “3 Beaten-Down Biotech Stocks to Buy Before the End of 2018 – Investorplace.com” on November 30, 2018, “Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of Ongoing Investigation of AbbVie’s Humira Sales Practices – PRNewswire” with a publish date: November 09, 2018, “Boehringer Ingelheim bails on biosimilars ex-U.S. – Seeking Alpha” and the last “7 Dividend Aristocrats to Buy for 2019 – Investorplace.com” with publication date: December 05, 2018.

AbbVie Inc. (NYSE:ABBV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.